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exploiting the immunomodulatory 
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cancer immunotherapy
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Cancer immunotherapy is gaining momentum in the clinic. The current challenge is to 
understand why a proportion of cancer patients do not respond to cancer immuno-
therapy, and how this can be translated into the rational design of combinatorial cancer 
immunotherapy strategies aimed at maximizing success of immunotherapy. Here, we 
discuss how tumors orchestrate an immunosuppressive microenvironment, which con-
tributes to their escape from immune attack. Relieving the immunosuppressive networks 
in cancer patients is an attractive strategy to extend the clinical success of cancer immu-
notherapy. Since the clinical availability of drugs specifically targeting immunosuppressive 
cells or mediators is still limited, an alternative strategy is to use conventional chemo-
therapy drugs with immunomodulatory properties to improve cancer immunotherapy. 
We summarize the preclinical and clinical studies that illustrate how the anti-tumor T 
cell response can be enhanced by chemotherapy-induced relief of immunosuppres-
sive networks. Treatment strategies aimed at combining chemotherapy-induced relief 
of immunosuppression and T cell-boosting checkpoint inhibitors provide an attractive 
and clinically feasible approach to overcome intrinsic and acquired resistance to cancer 
immunotherapy, and to extend the clinical success of cancer immunotherapy.
Keywords: cancer immunotherapy, immune checkpoint blockade, chemotherapy, tumor microenvironment, 
immunosuppression, anti-tumor immunity
introduction
Cancer immunotherapy – harnessing the patient’s immune system against cancer – is currently gaining 
momentum in the clinic. Clinical trials with immune checkpoint inhibitors show remarkable success 
in patients with advanced metastatic melanoma, non-small cell lung cancer, renal cancer, bladder 
cancer, and Hodgkin’s lymphoma (1–6). As a result, the journal Science proclaimed cancer immuno-
therapy as the breakthrough of 2013 (7). Furthermore, these encouraging results led to FDA approval 
of the immune checkpoint inhibitors ipilimumab (anti-CTLA-4), nivolumab, and pembrolizumab 
(anti-PD-1) in the past few years. Although cancer immunotherapy was proclaimed a breakthrough, 
a significant proportion of cancer patients do not show clinical benefit. There are various cancer cell-
intrinsic and cancer cell-extrinsic processes that regulate intrinsic or acquired resistance to cancer 
immunotherapy. Cancer cell-intrinsic characteristics like the mutational load have been reported to 
affect responsiveness to immunotherapy (8, 9). In terms of cancer cell-extrinsic processes, tumors 
exploit different strategies to induce immune escape by hampering the recruitment and activation 
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of effector T cells, and by creating a local immunosuppressive 
environment through recruitment of suppressive myeloid and 
regulatory T cells that dampen T cell effector functions. Which 
of these immune escape mechanisms are active in a certain tumor 
depends on the tumor type, tumor stage, and therapy history. A 
deeper understanding of the molecular mechanisms underlying 
these processes will contribute to the identification of biomarkers 
that can predict therapeutic efficacy of immunotherapy and to 
the design of combinatorial strategies aimed at maximizing the 
success of immunotherapy.
In this review, we discuss how tumor-induced immunosup-
pressive networks counteract efficacious anti-tumor immune 
responses, and how disruption of these networks can increase 
the anti-cancer efficacy of cancer immunotherapy with immune 
checkpoint inhibitors. Development and clinical testing of novel 
drugs specifically targeting immunosuppressive networks are 
ongoing and preliminary results are promising (10). An alterna-
tive strategy to relieve tumor-induced immunosuppressive states 
is to use conventional, and more easily accessible, anti-cancer 
treatment strategies with known immunomodulatory proper-
ties, such as chemotherapy, radiotherapy, and targeted therapy 
(11–15). Here, we focus on the immunomodulatory properties 
of conventional chemotherapy, and how these properties can be 
exploited to improve the anti-cancer efficacy of immune check-
point inhibitors.
Cancer immunotherapy: Opportunities 
and Challenges
Tumor-induced Mechanisms of immune escape
Cancers do not merely consist of tumor cells, but comprise a vari-
ety of cell types that together form the tumor microenvironment 
(TME) (Figures 1 and 2). Infiltrating immune cells are of special 
interest because of their paradoxical role in cancer progression. 
While some immune cell populations have pro-tumorigenic 
properties, others counteract tumorigenesis (16–18). Many 
tumors are characterized by an immunosuppressive TME, which 
makes it unfavorable for anti-tumor immunity. To mount effec-
tive anti-tumor immunity, tumor-associated antigens need to be 
sampled and processed by antigen-presenting cells (APCs). After 
receiving specific maturation signals, these APCs migrate to 
tumor-draining lymphoid organs where antigens are presented to 
T cells. Upon activation and proliferation, tumor antigen-specific 
T cells migrate to the tumor bed where they exert their cytotoxic 
function. At every step of this T cell priming and effector process, 
tumors employ strategies to hamper anti-cancer immunity.
Tumors often show dysfunctional recruitment and activation 
of dendritic cells (DCs), which are the most potent APCs for 
initiating immune responses. Several studies show that tumor-
infiltrating DCs display an immature phenotype (20, 21). Tumor-
derived factors like IL10, IL6, CSF1, and VEGF interfere with 
DC maturation, causing failure to migrate to the tumor-draining 
lymphoid organs, and to provide the appropriate co-stimulatory 
signals required to stimulate T cells (21). Although a thorough 
analysis of the antigen-presenting myeloid immune cell compart-
ment in the MMTV-PyMT mammary tumor model showed that 
intratumoral DCs are able to ingest and present tumor antigens to 
T cells, they fail to activate them (22). Nevertheless, even in these 
immunoevasive tumors, a rare population of IL12-expressing 
CD103+ DCs exists that is able to prime tumor antigen-specific 
T cells (23). Besides hampered T cell priming, the recruitment 
of activated T cells and their access into the tumor bed is often 
disrupted by the disorganized tumor vasculature and impaired 
expression of adhesion molecules on endothelial cells (24, 25). 
Some studies suggest that tumor-derived chemokines may cause 
selective trapping of T cells in the tumor stroma preventing 
access into the tumor bed (26). When tumor-specific T cells 
do succeed to reach the tumor, downregulation of MHC class I 
expression on tumor cells renders them invisible to T cell attack 
(27). Additionally, T cells face systemic and local tumor-induced 
immunosuppression, which limits their activation and function 
(28). Tumor-associated immunosuppression can be caused by 
tumor-infiltrating or systemically expanded myeloid cells or 
regulatory T cells (Tregs) that – directly or indirectly via secretion 
of soluble mediators – hamper T cell priming and effector func-
tion or even induce T cell death (28). These mechanisms will be 
discussed in more detail later.
enhancing Anti-Tumor immunity by immune 
Checkpoint inhibitors
To improve anti-tumor T cell immunity, different types of cancer 
immunotherapy approaches exist. While passive immuno-
therapy is based on adoptive transfer of (genetically engineered) 
autologous T cells, active immunotherapy boosts the endogenous 
immune response via cancer vaccines or inhibitors of immune 
checkpoints. The therapeutic effect of the latter is aimed at 
inhibition of negative immune regulatory pathways including 
cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and the 
programed cell death protein-1 (PD-1) receptor and one of its 
ligands, PD-L1 (B7-H1; CD274) (29). CTLA-4 is a member of 
the CD28 immunoglobulin superfamily and is expressed mainly 
on the surface of activated CD4+ T cells and Tregs, while absent 
on naïve T cells (30). CTLA-4 plays a central role in maintaining 
immune tolerance by competing with CD28 to bind the ligands 
CD80 and CD86 present on activated APCs to inhibit T cell co-
stimulation. The PD-1/PD-L1 axis shows similarities to that of 
CTLA-4. PD-1 is mainly expressed on activated T cells upon T cell 
receptor (TCR) engagement and on Tregs, while naïve and memory 
T cells do not usually express this surface marker. Recent studies 
suggest that PD-1, rather than being a marker of activated T cells, 
identifies exhausted T cells (31). PD-L1 is expressed on multiple 
cell types, whereas expression of PD-L2 (B7-DC; CD273) seems 
to be restricted to APCs (32, 33). Like CTLA-4, binding of PD-L1/
PD-L2 to its receptor results in an inhibitory signal that prevents 
T cell activation. While CTLA-4 blockade is hypothesized to act 
mainly in secondary lymphoid organs during the T cell priming 
phase, it is believed that blockade of PD-1 or PD-L1 targets the 
TME during the T cell effector phase (34). However, PD-1 can 
also play a role in the early T cell response as a regulator of CD8+ 
T cell expansion upon antigen recognition (35). In addition to 
its role in T cell priming, CTLA-4 also regulates the suppressive 
function of tumor-infiltrating Tregs (36, 37). In line with this, 
blockade of CTLA-4 in the B16 melanoma model acts locally 
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in the TME by inactivating Tregs in an Fc-dependent manner 
resulting in a favorable shift in the effector T cell/Treg ratio (38). 
The exact mechanisms of action of anti-CTLA-4 and anti-PD-1/
PD-L1 are not completely clear. Just recently, the combination of 
anti-CTLA-4 and anti-PD-1 was reported to significantly increase 
the fraction of melanoma patients responding to immunotherapy 
compared to anti-CTLA-4 monotherapy-treated patients (39), 
emphasizing the different modes of action of CTLA-4 and PD-1.
The rational of using CTLA-4 blockade in cancer therapy is 
to release the brake on pre-existing tumor-reactive T cells and to 
generate new T cell responses. Ipilimumab (anti-CTLA-4) was 
the first immune checkpoint inhibitor that yielded a significant 
increase in survival of patients with metastatic melanoma, 
for which all conventional therapeutic options had failed (1). 
Interestingly, a broadening of the tumor-reactive T cell reper-
toire was reported upon ipilimumab treatment (40). In a second 
clinical study, ipilimumab was combined with dacarbazine in 
metastatic melanoma patients resulting in prolonged survival 
compared to dacarbazine alone (41). In both studies, a fraction 
of patients showed long-term durable responses (42). Similarly, 
clinical trials with anti-PD-1 have shown tumor regression in a 
substantial fraction of cancer patients (3). These initial results 
lead to an immense increase in clinical trials with drugs targeting 
the PD-1/PD-L1 axis in different cancer types, and many report 
anti-tumor efficacy (3–6, 43). Recent clinical observations show 
that the combination of anti-CTLA-4 and anti-PD-1 is more 
effective than either monotherapy (39). Although very successful 
and promising, a significant proportion of cancer patients do 
not show long-term benefit of immune checkpoint inhibitors. 
Therefore, it is of utmost importance to mechanistically under-
stand intrinsic and acquired resistance to cancer immune 
checkpoint inhibitors, in order to identify biomarkers that can be 
used to pre-select those patients that will or will not benefit from 
cancer immunotherapy and to develop therapeutic strategies to 
overcome or bypass resistance mechanisms.
what are the Requirements for Therapeutic 
Response to Checkpoint inhibitors?
To predict the response to immunotherapy per patient and 
tumor type, several variables should be taken into account. For 
successful activation of a T cell-mediated anti-tumor immune 
response, T cells need to “see” the cancer cells with their TCR. 
In general, there are three classes of tumor antigens that can 
potentially be recognized by T cells: viral antigens, self-antigens, 
and neo-antigens. Our T cell repertoire is basically built to 
recognize and respond to viral antigens because these antigens 
are perceived as foreign or non-self. However, only a subset of 
established human cancers expresses viral antigens. During the 
T cell maturation process, thymic selection eliminates maturing 
lymphocytes that display a high avidity for self-antigens. As a 
consequence, only low-avidity self-specific T cells can be found in 
the peripheral T cell repertoire, which may not be ideal for cancer 
immunotherapy. Non-synonymous somatic mutations can give 
rise to neo-antigens toward which no central T cell tolerance is 
present. Recently, neo-antigen-specific T cell responses have been 
reported in melanoma patients (44–46), indicating that these 
mutations can be recognized by T cells and induce tumor-specific 
T cell responses. In line with this, the number of predicted neo-
antigens is linked with a metric for immune cytolytic activity 
based on gene expression in a large panel of cancer types (47). 
Thus, the extent of the mutational load of a certain tumor would 
serve – albeit at a low resolution – as a predictor of response to 
cancer immunotherapy. Indeed, a growing body of data supports 
this hypothesis (48). Whole-exome sequencing analyses revealed 
FiGURe 1 | establishment of the immune microenvironment during breast cancer progression in a conditional mouse model for mammary 
tumorigenesis. Female K14Cre;Cdh1F/F;Trp53F/F mice develop de novo invasive mammary tumors that closely resemble human invasive lobular carcinoma (19). 
Immunohistochemical staining on mammary tissue from K14Cre;Cdh1F/F;Trp53F/F mice obtained during different stages of mammary tumor progression. From top to 
bottom are represented wild-type mammary gland (top), early lesion (middle), established mammary tumor (bottom). From left to right, identification of different 
immune cell populations by H&E, F4/80 (macrophages), Ly6G (neutrophils), CD3 (total T cells), and FOXP3 (regulatory T cells) staining showing the dynamics of the 
tumor microenvironment. Arrowheads indicate FOXP3+ nuclei. Scale bar 100 μm.
FiGURe 2 | Combination strategies aimed at relieving the immunosuppressive tumor microenvironment with chemotherapy and 
potentiating cytotoxic T cells with immune checkpoint inhibitors. The tumor microenvironment is characterized by the presence of various immune 
cell types, including different subsets of adaptive immune cells and TAMs, MDSCs, and Tregs. The latter dampens the anti-cancer activity of T cells 
through several mechanisms. Moreover, cancer cells and myeloid cells express PD-L1/PD-L2 and APCs express CD80/CD86. Binding of these molecules 
to PD-1 and CTLA-4 respectively, expressed on T cells, results in inhibitory signals that counteract T cell activation and function. The immunomodulatory 
properties of different types of chemotherapeutic drugs can be exploited to enhance anti-tumor immunity. By optimally matching the immunomodulatory 
features of specific chemotherapeutic drugs with the T cell-boosting effect of immune checkpoint inhibitors, the efficacy of immunotherapy might be 
improved.
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that melanoma and lung cancer – the two cancer types that show 
promising responses to immunotherapy  –  bear relatively high 
mutational loads compared to other types of cancer due to their 
exposure to DNA damaging insults like UV radiation and tobacco 
smoke, respectively (49). Recent studies uncovered that a high 
mutational load is associated with long-term clinical benefit to 
checkpoint inhibitors (8, 9). However, not all cancer patients with 
tumors bearing a high mutational load respond to checkpoint 
inhibitors, and some patients bearing tumors with low mutational 
load do (8, 9). Together, these results suggest that the mutational 
load of tumors is correlated with response to immune checkpoint 
inhibitors, but it cannot solely be used to predict response.
A growing body of clinical observations suggests that the 
intratumoral presence of pre-existing T cells is required for 
clinical benefit of immunotherapy (50). PD-1 expression on 
tumor-infiltrating CD8+ T cells has been suggested to identify 
the repertoire of clonally expanded tumor-reactive T cells (51). 
In addition, T cell infiltration correlates with PD-L1 expression in 
tumors and is associated with increased responsiveness to drugs 
targeting the PD-1/PD-L1 axis in melanoma patients (50, 52, 53). 
Expression of PD-L1 in tumors is one of the main characteristics 
pursued as a potential biomarker for response to PD-1/PD-L1 
blockade. However, there are examples of tumors with high 
expression of PD-L1 that do not respond to PD-1 blockade, and 
PD-L1 negative tumors that do respond (53). Why certain tumors 
express PD-L1 and others do not remains to be elucidated.
Interestingly, expression of PD-L1 and responsiveness to 
immune checkpoint blockade is associated with genomic insta-
bility in different tumor types (54). Patients bearing mismatch-
repair-deficient colorectal cancer (CRC) respond better to 
anti-PD-1 therapy than mismatch-repair-proficient CRC patients 
(54). In line with this, a microsatellite instable (MSI) subset of 
CRC patients shows high T cell influx (55). However, this is 
counterbalanced by simultaneous upregulation of checkpoint 
molecules including PD-1, PD-L1, and CTLA-4 leaving T cells 
dysfunctional (55). Moreover, in breast cancer, the expression of 
PD-L1 is correlated with TIL infiltration, and is mostly prevalent 
in basal-like, hormone-receptor-negative, and triple-negative 
tumors (56, 57). Furthermore, in glioma patients increased 
expression of PD-L1 in tumors was correlated with PTEN loss 
(58), suggesting that patients bearing genetically unstable cancer 
types might benefit from treatment with checkpoint inhibitors. 
Intriguingly, not only cancer cells, but also tumor-infiltrating 
myeloid cells express PD-L1, and counteract anti-tumor immu-
nity in ovarian carcinoma and MSI-CRC (55, 59). Actually, 
PD-L1 expression on tumor-infiltrating immune cells has been 
suggested to be a better predictor of clinical response to anti-PD-
L1 therapy than PD-L1 expression on cancer cells (52). It will be 
interesting to explore, which other cancer types are characterized 
by the influx of PD-L1-expressing myeloid cells.
In conclusion, to increase the efficacy of immunotherapy in 
different types of cancer, we could consider manipulating the 
many variables that determine intrinsic and acquired resistance. 
While altering cancer cell-intrinsic characteristics, such as muta-
tional load or genomic instability, might be challenging, cancer 
cell-extrinsic characteristics, like an immunosuppressive TME, 
are easier to manipulate.
evasion from Cancer immunotherapy: 
Relieving immunosuppression as an 
Attractive Strategy to improve the efficacy 
of immune Checkpoint Blockade
Established tumors are characterized by an abundant influx 
of a variety of immune cells with immunosuppressive activity, 
including Tregs, myeloid-derived suppressor cells (MDSCs), and 
tumor-associated macrophages (TAMs) (Figures 1 and 2). There 
is accumulating evidence that interference with these immuno-
suppressive networks can improve anti-tumor immunity. Here, 
we discuss the different types of immunosuppressive immune 
cells present in the TME, and how blockade or reprograming of 
these cells or their downstream effects can enhance anti-tumor 
immunity and the efficacy of immune checkpoint blockade.
Regulatory T Cells
Regulatory T cells play an important role in maintaining homeo-
stasis during infections and in preventing the development of 
autoimmune diseases by blocking proliferation and cytotoxic 
activity of effector T cells. The history of Tregs goes back to the 
1970s, when it was discovered that a subpopulation of thy-
mocytes induced tolerance to certain antigens in mice (60). A 
turning point in the research of these “suppressor cells” came in 
1995. Tregs, phenotyped as CD4+CD25+ cells, were shown to be 
important for self-tolerance in mice, as inoculation of CD4+ cells 
depleted of CD4+CD25+ cells resulted in autoimmunity in nude 
mice (61). Another big step forward in the characterization of 
Tregs was the identification of FOXP3, a member of the fork-head/
winged-helix family of transcription factors and a key regulator 
of Treg development and function (62). In the following years, the 
knowledge of Tregs expanded enormously. Two subpopulations of 
Tregs were identified: natural Tregs and induced Tregs (or adaptive 
Tregs), which are formed in the thymus and in the periphery, 
respectively. Regardless of their origin, both natural and induced 
Tregs inhibit effector T cells (63).
In 1980, it was hypothesized that a T cell population in tumors 
suppresses anti-tumor immune responses (64). Indeed, many 
experimental studies support the notion that tumor-associated 
Tregs contribute to immune escape via suppression of anti-tumor 
CD8+ T cells. For example, elimination of Tregs in MO4 melanoma 
cell line-bearing mice results in T cell-dependent tumor rejection 
(65). Moreover, in a xenotransplant model for HER2+ ovarian 
cancer, adoptive transfer of autologous CD3+CD25− T cells 
and DCs loaded with HER2+ antigen results in T cell-mediated 
tumor regression, whereas concomitant transfer of Tregs blocks 
this antigen-specific immune response (66). Tregs not only sup-
press CD8+ T cells, but also CD4+ T cells, NK, NKT, and B cells 
(67). Tregs exert their immunosuppressive function either by direct 
suppression of effector cells, or indirectly by affecting the activa-
tion state of APCs. Importantly, in order to exert their functions, 
Tregs need to be activated via their TCR, but once activated their 
suppressive function is non-specific (68, 69). The direct T cell-
suppressive functions are mediated by release of cytokines, serine 
proteases and the expression of enzymes that catabolize ATP. For 
example, Tregs inhibit T cells via secretion of cytokines like TGFβ, 
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IL10, and IL35 (70–72) or even induce T cell apoptosis by the 
release of granzyme B (GRZMB) or perforin (73–75). In addition, 
Tregs express CD39 and CD73, two ectoenzymes that generate the 
immunosuppressive molecule adenosine from extracellular ATP 
(76). It has been shown that Tregs from CD39 knock-out mice fail 
to inhibit CD4+CD25− cell proliferation (76). Finally, CTLA-4+ 
Tregs can indirectly impair T cells by reducing the CD80/CD86 
levels on APCs (36).
Supporting these data, increased numbers of intratumoral Tregs 
correlate with worse overall survival in patients with ovarian can-
cer, breast cancer, gastric cancer, and hepatocellular carcinoma 
(66, 77–81). Interestingly, this is not true for CRC in which a high 
number of CD8+ cells and FOXP3+ cells correlates with a good 
prognosis (82). This may be explained by the fact that Tregs in CRC 
attenuate inflammation against gut microbiota that would other-
wise enhance tumor growth (82). These findings illustrate that the 
tumor context dictates the function of associated immune cells. 
Although strategies targeting CD25 (like the neutralizing mono-
clonal antibody daclizumab and the recombinant interleukin 2/
diphtheria toxin conjugate Ontak) showed transient depletion 
of peripheral Tregs and increased activity of CD8+ T cells, these 
approaches only result in a modest clinical benefit in cancer 
patients (83, 84). This might be explained by the fact that CD25 
is also expressed on active effector T cells, so the lack of specificity 
for Tregs might complicate their clinical applicability. Therefore, a 
mechanistic understanding of the role of Tregs in different tumor 
contexts will be important for the design of therapeutic strategies 
aimed at suppressing the downstream effects of Tregs.
Myeloid-Derived Suppressor Cells
The first report describing the existence of MDSCs showed that 
bone marrow-derived cells were able to suppress the killing activ-
ity of splenocytes in vitro (85). These cells were called “natural 
suppressor cells” or “null cells” because they did not express 
markers of B, T, or NK cells or macrophages (86). Subsequently, 
these cells were found to expand in inflammatory conditions 
and in tumor-bearing hosts (85, 87). In tumor-bearing mice, 
tumor-derived growth factors trigger the accumulation of T cell 
suppressive myeloid cells in the bone marrow and spleen (87, 
88). The identification of these cells was hampered by the lack 
of clear markers, which caused variation in terminology and 
ambiguity among researchers. In order to bring some clarity 
into the field, Gabrilovich and colleagues published a consensus 
paper in 2007 in which they coined the term “MDSC” to refer 
to a heterogeneous population of myeloid cells with the ability 
to suppress T cell activity (89). MDSCs consist of a group of 
immature and mature myeloid cells that are defined by their 
immunosuppressive function. Within the MDSC population, 
two subpopulations can be distinguished based on the expres-
sion of Ly6G and Ly6C: Ly6ChighLy6G− monocytic-MDSC and 
Ly6ClowLy6G+ granulocytic-MDSC. In humans, MDSCs are 
defined as CD11b+CD33+HLA-DR−Lin− cells with the addi-
tion of CD14 or CD15 to discriminate between monocytic- or 
granulocytic-MDSCs, respectively (90).
In patients with various cancer types, including melanoma, 
gastric, breast, and CRC, increased numbers of MDSCs in the 
circulation correlate with poor survival (91–93). Numerous 
cytokines have been implicated in the expansion of MDSCs dur-
ing cancer progression, including G-CSF, GM-CSF, and stem-cell 
factor (SCF or KIT ligand) (94–96).
Myeloid-derived suppressor cells exert their immunosup-
pressive function by different mechanisms, one of which is the 
consumption of essential amino acids from the environment. 
MDSCs frequently express high levels of arginase I, which catabo-
lizes arginine, thereby depriving T cells from arginine, which is 
essential for their metabolism and function (97, 98). l-Arginine is 
also the substrate of another enzyme highly expressed in MDSCs, 
called iNOS. The release of reactive oxygen species (ROS) and 
nitric oxide (NO) by iNOS can lead to the inhibition of MHC 
class II expression on APCs causing impaired antigen presenta-
tion to CD4+ T cells (99). Moreover, NO can cause apoptosis of 
CD8+ T cells (100). Another amino acid is tryptophan, whose 
breakdown by the enzyme IDO suppresses T cell proliferation. 
MDSCs isolated from human breast cancer tissues inhibit T cell 
proliferation and induce T cell apoptosis in an IDO-dependent 
manner (101). Moreover, IDO inhibitors enhance the therapeutic 
efficacy of anti-CTLA-4 treatment leading to intratumoral accu-
mulation of T cells and improved survival in the B16 melanoma 
model (102). Additionally, the amino acid cysteine is also impor-
tant for T cell activation and function. T cells depend on other 
cells (macrophages and DCs) for cysteine metabolism. MDSCs 
internalize cystine (formed of two cysteines linked via a disulfide 
bond), catabolize it to cysteine and, unlike macrophages and 
DCs, do not release it into the environment. Therefore, MDSCs 
limit the amount of cystine that macrophages and DCs can 
metabolize to activate T cells (103). Finally, MDSCs contribute to 
an immunosuppressive TME by inducing the development of Tregs 
in tumor-bearing mice, as adoptive transfer of MDSCs and CD4+ 
T cells in MCA26 colon carcinoma cell line-bearing irradiated 
mice, induces expression of FOXP3 in transferred T cells (104). 
Thus, these data suggest that MDSCs play an important role in 
creating an immunosuppressive network in tumors, supporting 
the idea that reprograming or depletion of MDSCs could benefit 
immunotherapy strategies. Strategies to inhibit MDSCs include 
blocking their development or recruitment, targeting their 
immunosuppressive molecules or depleting them.
Tumor-induced Neutrophils
In various cancer patients, a high neutrophil to T lymphocyte 
ratio in blood is associated with poor disease outcome (105, 
106). Recent studies have reported that neutrophils also expand 
in experimental mouse tumor models, and that they exert 
immunosuppressive activity. A distinguishing feature of murine 
neutrophils is the expression of Ly6G, a surface marker shared 
with granulocytic-MDSC. When the T cell suppressive ability of 
neutrophils is confirmed, they can be categorized into the granu-
locytic-MDSC population (107). We recently showed in a mouse 
model for de novo breast cancer metastasis that neutrophils have 
a pro-metastatic phenotype and exert their function through sup-
pression of CD8+ T cells. While depletion of Ly6G+ neutrophils 
results in decreased multi-organ metastasis, double depletion 
of neutrophils and CD8+ T cells reverses this phenotype (108). 
In line with this, chemotherapy-induced neutropenia correlates 
with improved overall survival in breast cancer patients (109). 
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The metastasis-promoting role of neutrophils has also been dem-
onstrated in UV-induced melanoma and in tumor inoculation 
models (110, 111). It would be interesting to study whether – as 
in the experimental tumor models – T cells in neutropenic cancer 
patients are more active. Interestingly, in 4T1-tumor-bearing 
mice, neutrophils inhibit the seeding of metastatic cells in the 
lung by the release of hydrogen peroxide (112). These data indi-
cate a controversial role of neutrophils in metastasis that might 
be explained by the differences in tumor subtype or tumor model.
We and others have shown that T cell-suppressive neutrophils 
accumulate systemically during cancer progression in a G-CSF-
dependent fashion (108, 113). In the transgenic MMTV-PyMT 
mammary tumor mouse model, tumor-derived G-CSF skews 
hematopoietic cell differentiation toward the granulocytic 
lineage in the bone marrow, resulting in increased numbers of 
immunosuppressive neutrophils in the circulation (113). In 
4T1 mammary tumor-bearing mice, TGFβ polarizes mature 
neutrophils from cytotoxic anti-tumor activity toward pro-tumor 
immature immunosuppressive neutrophils (114). This is in line 
with previous findings identifying TGFβ as one of the drivers of 
pro-tumor polarized neutrophils (115). As such, it is tempting to 
speculate that for those tumors characterized by pro-metastatic 
neutrophils, inhibition of these cells – either by targeting upstream 
or downstream molecules  –  may be an interesting strategy for 
therapeutic intervention, in particular when combined with 
cancer immunotherapy.
Tumor-Associated Macrophages
Macrophages are frequently the most predominant immune cell 
type in tumors. In the past, macrophages were subdivided into 
classically activated macrophages (M1) exerting microbicidal and 
anti-tumor activity, or alternatively activated macrophages (M2) 
exerting pro-tumoral, immunosuppressive, and tissue repair 
functions (116, 117). TAMs are frequently classified as M2 mac-
rophages. However, there is a growing realization that this black 
and white distinction of macrophage subsets is too simplistic and 
does not accurately reflect the heterogeneity, plasticity, and ver-
satility of macrophages (118). Transcriptome and bioinformatic 
analyses of cultured macrophages exposed to different stimuli 
revealed a spectrum of activation programs for each stimulus that 
goes beyond the M1 and M2 model (119). Based on these data, it 
is to be expected that TAMs will also change their phenotype and 
function according to the cytokine milieu present in a specific 
tumor type. In the vast majority of cancers, high intratumoral 
macrophage density correlates with poor prognosis (120, 121). 
However, macrophages in CRC are associated with good prog-
nosis, and in other types of cancers, like prostate and lung cancer, 
their role is still controversial (122). Depletion of macrophages by 
genetic ablation of CSF-1 in the MMTV-PyMT mammary tumor 
model reduces metastasis formation without affecting primary 
tumor growth (123). Likewise, several other experimental studies 
have reported a pro-metastatic role of macrophages (124, 125). 
TAMs produce a variety of factors that foster tumor growth and 
invasiveness, angiogenesis, and immunosuppression (120, 124, 
126).
Tumor-associated macrophages exert their immunosuppres-
sive activity in a similar fashion as that of MDSCs. TAMs can 
express various enzymes like arginase 1, IDO (127–129), and 
cytokines like IL10 (130). Another mechanism by which TAMs 
suppress T cells is the upregulation of PD-L1. In hepatocellular 
carcinoma, high density of peritumoral macrophages that express 
PD-L1 correlates with worse overall survival (131). Co-culture 
experiments showed that PD-L1+ macrophages suppress T cell 
activity unless anti-PD-L1 antibody is added in the culture (131). 
Based on these immunosuppressive properties, it is tempting to 
speculate that interference with TAMs will unleash anti-tumor 
immunity. Indeed, this idea has recently been supported by 
experimental studies in mouse models for glioblastoma and 
pancreatic cancer showing that CSF-1/CSF-1R pathway blockade 
can shift TAM polarization toward an anti-tumor phenotype, 
resulting in enhanced CD8+ T cell-mediated anti-tumor immu-
nity (132, 133). Similarly, targeting the CCL2/CCR2 chemokine 
pathway  –  involved in recruitment of monocytes and mac-
rophages – relieves the immunosuppressive phenotype of TAMs 
and enhances anti-tumor CD8+ T cell responses (134, 135). Based 
on these encouraging results, clinical trials are ongoing in which 
compounds targeting TAMs are being tested in cancer patients. 
Preliminary results of a clinical trial with anti-CSF-1R in patients 
with various types of solid malignancies showed a decrease in 
TAMs and an increase in intratumoral CD8/CD4 ratio (10).
Blocking the Suppressors to Release Anti-Tumor 
T Cells
As discussed above, many immunosuppressive cells and media-
tors can be identified in the TME that dampen anti-tumor T cell 
responses and may contribute to immune escape upon cancer 
immunotherapy. The combination of compounds that relieve 
immunosuppression with T cell-boosting therapy seems attrac-
tive to overcome immune tolerance toward the tumor.
Regulatory T cells seem to be interesting targets, since, as dis-
cussed earlier in this review, these cells suppress the functionality 
of CD4+ and CD8+ effector cells. In line with this, in the transgenic 
TRAMP prostate cancer model – engineered to express prostate-
specific antigen (PSA) – Treg-depletion enhances IFNγ produc-
tion by PSA-specific CD8+ T cells (136). This augmented effect of 
anti-tumor immunity is further enhanced by CTLA-4 blockade, 
and results in delayed tumor growth. Interestingly, the same 
experiments performed in the parental TRAMP model show only 
a modest activation of PSA-specific T cells upon anti-CD25 and 
anti-CTLA-4, and no survival benefit, suggesting the requirement 
of a tumor-specific antigen for this anti-tumor response (136). 
In the ID8 ovarian cancer model, tumor-infiltrating Tregs – which 
express both CTLA-4 and PD-1 – are reduced upon CTLA-4 and 
PD-1 dual blockade coinciding with increased tumor-infiltrating 
CD8+ T cells (137). However, additional depletion of Tregs does 
not further enhance this effect. In the same model, blockade of 
PD-L1, expressed on tumor cells and tumor-infiltrating immune 
cells, reduces the number of MDSCs and Tregs and enhances the 
frequency of effector T cells, resulting in prolonged survival 
(138). Furthermore, in a mouse model for rhabdomyosarcoma, 
PD-1 blockade increases the number of tumor-infiltrating CD8+ 
T cells, but does not change their activation status. Upon interfer-
ence with the chemokine receptor CXCR2, which prevents MDSC 
trafficking into the tumor, enhanced activation of CD8+ T cells 
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is observed (139). Blockade of CXCR2 improves the therapeutic 
efficacy of anti-PD-1 treatment resulting in a significant survival 
benefit (139). Moreover, in a mouse model of pancreatic ductal 
adenocarcinoma, blockade of CSF-1/CSF-1R signaling results in 
macrophage reprograming to support anti-tumor immune func-
tion and modestly delays tumor growth (133). TAMs obtained 
from anti-CSF1 treated mice are impaired in suppressing CD8+ 
T cell proliferation compared to control TAMs. The induction of 
CTLA-4 expression on CD8+ T cells and PD-L1 expression on 
tumor cells suggests the onset of acquired resistance to effective 
anti-tumor immune responses. Combining anti-CTLA-4 and 
anti-PD-1 with a CSF-1R inhibitor shows profound synergy with 
a significant reduction in tumor burden (133). Thus, together 
these results indicate that alleviation of immunosuppression 
reactivates anti-tumor immunity, which can be further enhanced 
by checkpoint inhibition.
immunomodulatory Properties of 
Chemotherapeutic Drugs
Although various novel compounds targeting tumor-associated 
myeloid cells and their immunosuppressive mediators are being 
developed and tested, their clinical availability is still limited. 
An alternative and clinically available strategy is to relieve 
immunosuppression by exploiting the immunomodulatory 
effects of conventional anti-cancer strategies like chemotherapy 
(Figure 2). The impact of chemotherapeutic drugs on the propor-
tion and phenotypic and functional characteristics of immune 
cells is to a great extent dictated by the type of drug and the 
dosing scheme: while high-dose chemotherapy usually results in 
lympho- or myelodepletion, low-dose (metronomic) treatment 
has more subtle anti-angiogenic and immunomodulatory effects 
(140, 141). In this section, we discuss the effects of chemotherapy 
on the immunosuppressive TME.
The impact of Chemotherapy on T Cell Priming
Optimal T cell priming is dependent on antigen processing, pres-
entation, and co-stimulation by properly matured and activated 
DCs. As discussed, impaired DC function and T cell priming are 
important mechanisms of immune escape by tumors. Certain 
chemotherapeutics induce anti-cancer immune responses by 
improving the recruitment and functionality of intratumoral DCs 
(142, 143). For example, low-dose cyclophosphamide promotes 
DC maturation (144). Besides the enhanced release of tumor 
antigens through induction of cancer cell death, chemothera-
peutics, including oxaliplatin, doxorubicin, mitoxantrone, and 
melphalan, induce HMGB1 release and calreticulin translocation 
in cancer cells, facilitating antigen uptake by DCs and subse-
quent T cell stimulation (145–147). In addition, in the MCA205 
fibrosarcoma model, anthracyclins induce the differentiation of 
myeloid cells in the tumor bed toward a DC-like phenotype in an 
ATP-dependent manner (142). In these relatively high immuno-
genic tumor models, the activated T cells subsequently enhance 
the anti-cancer efficacy of chemotherapy (142, 143, 145).
In less immunogenic models, such as de novo tumorigenesis 
models, an important role for T cells in chemotherapy efficacy 
is lacking (120, 148, 149). One possible explanation is that 
spontaneously arising tumors are characterized by local 
and systemic immunosuppression, which may overrule any 
chemotherapy-induced T cell responses. Indeed, in the MMTV-
PyMT mammary tumor model, TAM-derived IL10 indirectly 
blocks anti-tumor CD8+ T cell activity by suppressing IL12 
expression by intratumoral DCs upon paclitaxel treatment (149). 
These results apply to human breast cancer patients since low 
CD68+ macrophage over CD8+ T cell ratio prior to neo-adjuvant 
chemotherapy correlates with a better pathologic response (120). 
Moreover, high levels of IL12A mRNA in human breast cancer 
samples correlates with expression of DC-related transcription 
factors and GRZMB, CD8A, and IFNγ expression, suggesting 
an active anti-tumor T cell response (149). However, the role of 
TAMs and their potential suppressive function in cancer patients 
was not evaluated. Together, these results suggest that therapeutic 
targeting of TAMs could enhance the functionality of intratumoral 
DCs and anti-tumor T cell responses in chemotherapy treatment.
impact of Chemotherapy on Tregs
With the knowledge that Tregs play an important role in sup-
pressing effector T cell responses, a lot of effort has been put 
into the identification of chemotherapeutic drugs that target 
these cells. The best studied is cyclophosphamide, an alkylating 
agent, which crosslinks DNA, thus interfering with replication. 
Cyclophosphamide is known for its dose-dependent effect on 
the immune system. High doses of cyclophosphamide result 
in immunosuppression by reducing T cell proliferation and 
inducing apoptosis, thus making it useful for the prevention of 
graft-versus-host disease or rejection of transplanted organs (150, 
151). In contrast, low doses selectively ablate Tregs and dampen 
their T cell suppressive ability (152). While the anti-tumor effect 
of high-dose cyclophosphamide is mainly due to its cytotoxic 
activity against cancer cells, the anti-tumor effect of low-dose 
cyclophosphamide depends on its immune-modulatory effects 
(153). Indeed, studies in T cell-deficient mice bearing inoculated 
tumors show loss of the anti-cancer activity of low-dose cyclophos-
phamide (153, 154). Moreover, reinfusion of CD4+CD25+ T cells 
in tumor-bearing mice, pre-treated with low-dose cyclophospha-
mide, abrogated the anti-tumor effect of the drug, emphasizing 
that Tregs counteract the therapeutic efficacy of the drug (153). In 
line with this, patients with different types of metastasized solid 
tumors receiving low-dose metronomic cyclophosphamide show 
a specific decrease of Tregs in the periphery with concomitant 
enhancement of NK lytic activity and T cell proliferation (155). In 
cancer patients receiving higher doses of metronomic cyclophos-
phamide, all lymphocyte populations were depleted, emphasizing 
the importance of accurate drug dosing to achieve selective Treg 
depletion (155). It has been proposed that the increased sensitiv-
ity of Tregs for cyclophosphamide is linked to their low ATP levels. 
Low levels of ATP result in decreased synthesis of glutathione, 
which is important for cyclophosphamide detoxification (156).
Another chemotherapeutic drug affecting Tregs is gemcitabine, 
a nucleoside analog interfering with DNA replication. In an 
orthotopic pancreatic cancer model, gemcitabine reduces the 
percentage of Tregs in the tumor resulting in a small but significant 
survival benefit (157). Whether this also results in improved CD8+ 
and CD4+ T cell activity remains unknown. A study performed in 
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cancer patients showed that the percentage of Tregs in blood was 
decreased after gemcitabine treatment (158). Among the CD4+ 
cells, Tregs were identified as the most proliferative cells, which may 
explain the selectivity of gemcitabine for these cells. However, the 
effect of gemcitabine on other T cell populations was not assessed 
in this study (158). Also, other (combinations of) chemotherapy 
drugs have been reported to influence the presence or function 
of Tregs (159, 160).
Chemotherapeutics with inhibitory Activity 
Toward Tumor-Associated Myeloid Cells
Several chemotherapy drugs have been implicated in the selec-
tive reduction of MDSCs in the tumor and spleen of tumor-
bearing mice (161, 162). In an EL4 inoculation tumor model, 
a set of chemotherapy drugs was tested for their influence on 
the number of splenic and intratumoral MDSCs (161). This 
study showed that high-dose gemcitabine and 5-fluorouracil 
(5-FU), two anti-metabolite drugs that interfere with DNA 
replication, reduce MDSC accumulation (161). Consequently, 
5-FU-mediated MDSC depletion results in increased IFNγ-
producing intratumoral CD8+ T cells. This effect is reverted by 
adoptive transfer of MDSCs, suggesting that the effect of 5-FU 
is exerted through MDSCs (161). Similar results were obtained 
in the MCA203 cell line inoculation sarcoma model combined 
with cytotoxic T cell transfer (163), highlighting the critical 
role of MDSCs in dampening T cell activity upon 5-FU treat-
ment. While the exact mechanisms underlying the selectivity of 
5-FU for MDSCs are unknown, it has been proposed that 5-FU 
inhibits the enzyme thymidylate synthase and that the resistance 
to 5-FU is due to insufficient inhibition of this enzyme (164). 
Indeed, low levels of thymidylate synthase are found in MDSCs 
compared to splenocytes and EL4 tumor cells, suggesting that 
5-FU selectivity for MDSCs could be due to this low enzymatic 
expression (161).
High-dose gemcitabine induces similar effects on MDSCs 
as 5-FU (162). In vitro analyses of splenocytes from TC-1 lung 
cancer-bearing mice showed the cytotoxic specificity of gem-
citabine for MDSCs, while CD4+, CD8+ T cells, and B cells are 
unaffected (162). Although the exact mechanism underlying this 
specificity has not been identified, it has been hypothesized that 
gemcitabine induces apoptosis in MDSCs (162). Yet, a thorough 
mechanistic analysis of gemcitabine-induced apoptotic cell death 
in various immune cell populations has not been performed. In 
the 4T1 breast cancer mouse model, gemcitabine treatment also 
reduces splenic MDSC accumulation, which results in increased 
proliferation and IFNγ production by splenic lymphocytes upon 
antigen stimulation compared to untreated mice (165). However, 
no difference in anti-cancer efficacy of gemcitabine was observed 
between immunocompetent and nude mice, indicating a T cell-
independent mechanism of 4T1 tumor control by gemcitabine 
(165). Perhaps, this observation might be explained by the pres-
ence of other immunosuppressive cells in the TME, like Tregs or 
macrophages.
The beneficial effect of chemotherapeutic drugs on the immu-
nosuppressive TME is not only a direct result of reduced MDSC 
numbers, but also a result of a more favorable phenotype of the 
remaining MDSCs. For example, in the 4T1-Neu mammary 
tumor model, docetaxel reduces splenic granulocytic-MDSCs and 
enhances CD8+ and CD4+ cytotoxic activity (166). The remain-
ing MDSCs exhibit a different phenotypic profile compared to 
MDSCs from untreated mice. In line with these in vivo findings, 
MDSCs pre-treated with docetaxel induce the proliferation of 
OVA-exposed OT-II CD4+ T cells compared to untreated MDSCs 
in vitro, suggesting that docetaxel treatment induces a phenotypi-
cal switch to a more favorable state (166). Likewise, doxorubicin 
selectively decreases the proportion of MDSCs in the 4T1 breast 
tumor model via apoptosis and subdues the immunosuppressive 
phenotype of the remaining MDSCs. The remaining MDSCs have 
a lower expression of immunosuppressive molecules like ROS, 
ARG-1, and IDO (167). This less suppressive environment caused 
by doxorubicin enhanced the activity of adoptively transferred T 
helper cells (167). Interestingly, some subpopulations of MDSCs 
may be more susceptible to chemotherapy than others. Whether 
chemotherapy selectively depletes pro-tumorigenic MDSCs or 
skews them toward an anti-tumor phenotype is unknown. Future 
studies using lineage tracing methodologies would provide more 
insight into this topic.
Besides the favorable immunomodulatory “off-target” effects 
of various chemotherapeutic drugs, these drugs can at the same 
time exert less desirable functions. For instance, in addition to 
its inhibitory effect on Tregs, cyclophosphamide increases the 
number of CD11b+Gr1+ MDSCs. In a transgenic mouse model 
for melanoma, a single injection of low-dose cyclophosphamide 
increases the accumulation of MDSCs in the tumor and spleen, 
stimulates their immunosuppressive ability by inducing NO and 
ROS production, and reduces splenocyte proliferation (168). 
In line with these findings, MDSCs accumulate in the blood of 
breast cancer patients after treatment with doxorubicin or cyclo-
phosphamide (169). This may be due to IFNγ release by CD4+ 
and CD8+ T cells that promotes survival of MDSCs (170). Based 
on these data, a combination of cyclophosphamide and cancer 
immunotherapy might not work; however, additional studies in 
other tumor models should be performed to test this.
Another study underscoring the complex impact of chemo-
therapy on myeloid cells shows that in EL4-tumor-bearing mice 
5-FU induces IL1β secretion in MDSCs in an Nlrp3 inflamma-
some-dependent manner (171). Using depletion experiments 
and knock-out mice, it was shown that the MDSC-derived IL1β 
triggers IL17 production by CD4+ T cells, which limits the anti-
cancer efficacy of 5-FU (171). These data highlight that the effect 
of certain chemotherapy drugs is not simply limited to depletion 
of immunosuppressive cells but these drugs also change the 
functionality of cells that may impair their efficacy. These results 
suggest that the combination of chemotherapeutic and immu-
nomodulatory compounds must be chosen carefully to increase 
their anti-cancer efficacy (172).
While several chemotherapy drugs have been reported to 
target MDSCs, thus far only one drug seems to strongly affect 
TAMs. Trabectedin, a drug that binds DNA and affects tran-
scription and DNA repair pathways, depletes macrophages, and 
suppresses the differentiation of monocytes in the tumor bed 
in the transplantable MN/MCA1 fibrosarcoma tumor model 
through a TRAIL-dependent mechanism (173). Importantly, this 
macrophage selectivity is also observed in sarcoma patients after 
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trabectedin neo-adjuvant treatment (173). It would be interesting 
to assess whether the anti-cancer activity of trabectedin is CD8+ 
T cell mediated. The macrophage-depleting effect of trabectedin 
makes it an interesting candidate for combination strategies with 
immunotherapy.
As discussed before, many studies illustrate the complexity of 
immunomodulation by conventional chemotherapeutics, which 
is highly context-dependent. The differential effect on specific 
immune cells of different types of chemotherapeutics is to a large 
extent dependent on the timing and dosing schedule. While high-
dose chemotherapy often depletes immune cell subsets, low-dose 
metronomic chemotherapy exerts a more subtle anti-angiogenic 
and immunomodulatory mode of action (140, 141). It will be 
interesting to perform a side-by-side comparison of various types 
of chemotherapies administered at high versus low (metronomic) 
dose and evaluate their immunomodulatory effects, followed by 
more mechanistic studies. Ideally, these types of experiments 
would be performed in clinically relevant mouse models that 
faithfully recapitulate human cancer (Box 1) to facilitate clinical 
translation.
Future Perspectives: exploiting the 
immunomodulatory Properties of 
Chemotherapeutic Drugs to improve 
Cancer immunotherapy
Given their immunomodulatory properties, conventional 
chemotherapy drugs are interesting candidates to combine with 
T cell-boosting immunotherapy  –  a concept termed chemo-
immunotherapy (174). Clinical trials report enhanced anti-tumor 
T cell responses in cancer patients treated with chemotherapy 
in combination with cancer vaccines (13). Moreover, clinical 
testing of chemotherapy combined with other immunotherapy 
approaches like adoptive transfer of (genetically engineered) 
autologous T cells or toll-like receptor (TLR) agonists are likely 
to be explored in the near future. Indeed, various experimental 
studies support the concept that chemotherapy-induced relief of 
immunosuppression could improve cancer immunotherapy. In a 
passive immunotherapy setting, in the MC203 fibrosarcoma and 
TC-1 lung cancer cell line inoculation models, low-dose gemcit-
abine and 5-FU reduced the splenic population of CD11b+Gr1+ 
MDSCs, resulting in enhanced anti-tumor activity of adoptively 
transferred tumor-specific CTL (163).
The results obtained in preclinical models combining chemo-
therapeutics with immune checkpoint inhibitors are promising. 
The immunomodulatory effects of melphalan – administered in a 
subtherapeutic dose – synergizes with CTLA-4 blockade in a plas-
macytoma model (175). In vitro assays revealed that splenocytes 
obtained from melphalan-treated mice co-cultured with anti-
CTLA-4 induced tumor cell cytotoxicity, while splenocytes from 
non-treated mice –  irrespective of CTLA-4 blockade – did not 
(175). Furthermore, in the poorly immunogenic AB-1 malignant 
mesothelioma and Lewis lung cancer (LLC) inoculation tumor 
models, a combination therapy of gemcitabine and CTLA-4 
blockade synergizes, inducing potent anti-tumor immune 
responses and subsequent regression of tumors in a CD4- and 
BOX 1 | experimental mouse models to study the anti-tumor immune 
response.
Understanding the complex crosstalk between innate and adaptive immune 
cells and (disseminated) cancer cells requires the use of preclinical mouse 
models that faithfully recapitulate human cancer. The most widely used 
experimental mouse models are carcinogen-induced cancer models and cell 
line inoculation models. The latter is based on inoculation of large numbers 
of (genetically modified) homogenous cancer cells grown in 2D conditions. 
Implantation of these cells often results in massive cell death, thereby priming 
an effective anti-tumor immune response. Shaping of the tumor immune 
microenvironment during cancer progression in these models can hardly take 
place in the short amount of time that it takes for transplanted tumors to grow 
to their maximum tolerated size. Of notice, when implanting human cancer 
cells, either patient-derived tumor material or established human cancer cell 
lines, immunocompromised mice are used, thereby excluding the important 
role of the adaptive immune system.
While cell line inoculation models proved useful to decipher some 
aspects of the anti-tumor immune response, we should keep in mind that 
these models do not reflect physiological processes as they occur in human 
patients. Genetically engineered mouse (GEM) models, which develop 
de novo cancers, generally mimic human cancer genetically  –  because of 
the introduction of specific driver mutations – and histopathologically (180). 
In addition, tumor progression occurs in a multi-step nature in their natural 
microenvironment shaping the local immune responses (Figure 1), therefore 
mimicking the human setting. In contrast to inoculation models expressing 
known tumor antigens, the anti-tumor immune response in GEM models 
can be considered a black box. Due to their cellular and genetic hetero-
geneity, GEM models induce a variety of T cell responses directed against 
multiple unknown tumor neo-antigens, which faithfully reflects human cancer. 
Interestingly, comparative studies have shown that inoculation models greatly 
differ from GEM models in terms of response to anti-cancer therapies and 
endogenous T cell responses (181, 182). The advantages and disadvantages 
of different experimental mouse models in studying responsiveness to anti-
cancer therapy have been recently discussed (14, 183).
CD8-dependent manner (176). In addition, in a subcutaneous 
murine mesothelioma model, synergy is observed between cis-
platin and CTLA-4 blockade, resulting in a profound anti-tumor 
effect that is characterized by increased influx and activation of 
CD4+ and CD8+ T cells in the tumor (177). Moreover, preclinical 
studies in mice show that doxorubicin, cisplatin, and paclitaxel 
in addition to their immunomodulatory role, can sensitize tumor 
cells for CTL attack in a direct manner (178). Here, chemotherapy 
causes increased permeability of tumor cell membranes to 
GRZMB, which sensitizes cancer cells to the cytotoxic effects 
of T cells and improved different cancer immunotherapy strate-
gies (178). Together, these preclinical studies  –  albeit limited 
numbers  –  show the potential to exploit immunomodulatory 
chemotherapeutic drugs to improve the efficacy of checkpoint 
blockade.
Clinical trials that evaluate the combination of chemothera-
peutic drugs and checkpoint inhibitors in cancer patients are 
still limited. Some studies in melanoma and lung cancer have 
used chemotherapeutics in combination with checkpoint block-
ade resulting in improved survival compared to chemotherapy 
alone (41, 179). However, the rational of these studies was not 
to evaluate the effect of treatment on the immunosuppressive 
microenvironment. Moreover, the design of clinical trials makes 
it impossible to perform a structural comparison in patients to 
study the effect of the immunosuppressive microenvironment 
on immunotherapy efficacy and whether this efficacy can 
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be enhanced by adding chemotherapeutics to the treatment 
regimen. Therefore, we need to rely on preclinical research in 
mouse tumor models that faithfully recapitulate human cancer 
in terms of the genetic composition, anti-tumor immunity, 
and the immunosuppressive TME (Box  1). Results obtained 
in mouse models that mimic human cancer might shape the 
design of clinical trials and guide toward interesting treatment 
strategies. There are still various important questions that need 
to be addressed to maximally exploit the therapeutic efficacy 
of chemotherapy and immunotherapy combinations, like the 
determination of the most optimal combinations. Based on 
preclinical findings, different cancer types will likely require 
different combinations of therapy. In addition, despite the 
devastating effects of metastatic disease, mechanistic insights 
into the site-specific therapeutic response profiles and resistance 
mechanisms of cancer immunotherapy are completely lacking. 
Moreover, it is critical to gain insights into the mechanisms 
underlying intrinsic and acquired resistance to cancer immu-
notherapy. To answer these questions within the next decade, 
it is critical that basic researchers and clinicians intensify their 
efforts to join forces, so that results from preclinical research 
can guide the design of clinical trials, and the results from 
clinical trials, in turn, can guide mechanistic studies in mouse 
models. Together, these efforts will improve treatment strategies 
using chemotherapeutics to alleviate immunosuppression and 
enhance cancer immunotherapy.
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